Bai Ausaitu (02315) technology platform fruitful frequent Marke, Tubulis and other international cooperationJer PhilippeOceanrq86395624659togolevioletta32997FjeW11Ah8aAOmutanwe F10ChinaAIO1

Recently, the announcement of a number of collaborations and research progress between BeiGene (02315) and Merck, Tubulis, and IDEAYA has attracted market attention, highlighting its platform strength and international collaboration effectiveness in the field of antibody drug research and innovative delivery technology. Recently, BeiGene's partner IDEAYA Biosciences focused on the joint development of the bispecific antibody-drug conjugate (bsADC) IDE034 (BCG034) at its 10th Research Day. The drug, based on BeiGene's RenLite platform, targets B7-H3 and PTK7, carrying the company's novel Linker & Payload platform BLD1102. Preclinical data has shown significant efficacy in specific tumor models, especially when used in combination with the PARG inhibitor IDE161, displaying tumor-specific synergistic effects. IDEAYA plans to submit a new drug clinical trial application in the fourth quarter of this year, with indications covering multiple cancers such as lung and colorectal cancer. In addition, BeiGene recently announced partnerships with German Tubulis and global technology leader Merck. Tubulis plans to leverage BeiGene's internally developed fully human antibodies to advance their ADC product development and commercialization. BeiGene will receive an upfront payment and have the right to receive development, regulatory, and commercialization milestone payments, as well as single-digit net sales royalties. The collaboration with Merck focuses on advancing the development of antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP).